Brief: Positive Phase 3 Results For Denifanstat For The Treatment Of Moderate To Severe Acne To Be Presented At The Eadv Congress 2025 By Partner Ascletis
17/09/2025 14:15
Sept 17 (Reuters) - Sagimet Biosciences Inc SGMT.O: POSITIVE PHASE 3 RESULTS FOR DENIFANSTAT FOR THE TREATMENT OF MODERATE TO SEVERE ACNE TO BE PRESENTED AT THE EADV CONGRESS 2025 BY PARTNER ASCLETIS SAGIMET BIOSCIENCES INC - DENIFANSTAT GENERALLY WELL TOLERATED SAGIMET BIOSCIENCES INC - DENIFANSTAT MEETS ALL PRIMARY AND SECONDARY ENDPOINTS Source text: ID:nGNX6vLqTL Further company coverage: SGMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage